Table 4.
The aHRs (95% CI) for retinal vein occlusion by multivariable Cox regression.
| Variable | aHR (95% CI) | ||
|---|---|---|---|
| For RVO risk | For CRVO risk | For BRVO risk | |
| Cohort | |||
| Non-sinusitis | Reference | Reference | Reference |
| Sinusitis | 1.28 (1.13–1.44) | 1.51 (1.16–1.96) | 1.36 (1.12–1.65) |
| Year of index | |||
| 2002–2004 | Reference | Reference | Reference |
| 2005–2007 | 1.08 (0.94–1.25) | 1.02 (0.76–1.37) | 1.01 (0.81–1.26) |
| 2008–2010 | 0.93 (0.76–1.13) | 0.52 (0.33–0.83) | 0.76 (0.56–1.03) |
| 2011–2013 | 0.87 (0.68–1.11) | 0.78 (0.48–1.27) | 0.52 (0.34–0.78) |
| 2014–2016 | 0.83 (0.57–1.22) | 0.29 (0.09–0.93) | 0.41 (0.20–0.84) |
| 2017–2019 | 0.75 (0.36–1.53) | 0.71 (0.17-3.00) | Not estimated |
| Sex | |||
| Male | 1.17 (1.04–1.31) | 1.12 (0.87–1.43) | 1.12 (0.94–1.35) |
| Female | Reference | Reference | Reference |
| Age at T0 | |||
| < 40 | 0.13 (0.06–0.27) | 0.08 (0.02–0.26) | 0.09 (0.03–0.29) |
| 40–49 | 0.61 (0.29–1.31) | 0.29 (0.09–0.97) | 0.66 (0.21–2.10) |
| 50–59 | Reference | Reference | Reference |
| 60–69 | 1.25 (0.59–2.65) | 0.77 (0.24–2.49) | 1.39 (0.44–4.40) |
| 70–79 | 1.51 (0.71–3.23) | 0.76 (0.23–2.48) | 1.59 (0.50–5.06) |
| ≥ 80 | 1.61 (0.74–3.50) | 0.94 (0.27–3.21) | 1.42 (0.43–4.71) |
| Urbanization level | |||
| 1 (high) | Reference | Reference | Reference |
| 2 | 1.03 (0.89–1.19) | 0.86 (0.63–1.17) | 0.94 (0.74–1.19) |
| 3 | 0.98 (0.82–1.17) | 0.89 (0.61–1.30) | 1.13 (0.85–1.48) |
| 4 | 1.07 (0.88–1.29) | 0.79 (0.51–1.23) | 0.92 (0.66–1.27) |
| 5 | 0.78 (0.47–1.29) | 1.01 (0.39–2.60) | 0.90 (0.41–1.97) |
| 6 | 1.10 (0.81–1.50) | 1.02 (0.52–1.99) | 1.39 (0.87–2.22) |
| 7 (low) | 0.87 (0.60–1.27) | 0.69 (0.29–1.65) | 1.23 (0.72–2.12) |
| Type of insurance coverage | |||
| Government | 0.84 (0.67–1.07) | 0.86 (0.52–1.43) | 0.88 (0.61–1.28) |
| Labor | Reference | Reference | Reference |
| Farmers’ /Fishermen’s membership | 1.07 (0.89–1.30) | 0.93 (0.60–1.44) | 0.95 (0.70–1.30) |
| Low-income households | 0.73 (0.27–1.96) | 0.82 (0.11–5.86) | 0.46 (0.06–3.27) |
| Non-labor force/unemployed | 0.92 (0.77–1.09) | 0.93 (0.65–1.34) | 0.90 (0.68–1.18) |
| Others | 0.75 (0.48–1.18) | 0.84 (0.34–2.07) | 1.04 (0.57–1.91) |
| Length of hospital stay (within 180 days before T0) | |||
| 0 day | Reference | Reference | Reference |
| 1–6 days | 1.07 (0.53–2.18) | 1.41 (0.34–5.87) | 0.79 (0.19–3.25) |
| >=7 days | 0.84 (0.31–2.28) | Not estimated | 0.59 (0.08–4.33) |
| Co-morbidity (within 180 days before T0) | |||
| Hypertension | 1.62 (1.31-2.00) | 1.90 (1.22–2.98) | 1.26 (0.89–1.79) |
| Diabetes mellitus | 1.49 (1.20–1.85) | 1.62 (1.03–2.55) | 1.46 (1.04–2.05) |
| Hyperlipidemia | 0.93 (0.73–1.19) | 0.75 (0.43–1.31) | 0.80 (0.54–1.20) |
| Ischemic heart diseases | 1.08 (0.82–1.42) | 1.79 (1.08–2.98) | 1.17 (0.77–1.77) |
| Peripheral vascular disease | 0.44 (0.11–1.76) | Not estimated | 0.52 (0.07–3.72) |
| Ischemic stroke | 0.99 (0.61–1.59) | 0.73 (0.23–2.32) | 1.18 (0.60–2.34) |
| Hemorrhagic stroke | 1.64 (0.73–3.68) | 2.82 (0.68–11.60) | 1.25 (0.31–5.10) |
| Chronic kidney disease | 4.29 (2.94–6.28) | 5.10 (2.36–11.01) | 4.66 (2.63–8.25) |
| COPD | 1.18 (0.88–1.58) | 1.07 (0.57–1.99) | 1.07 (0.66–1.71) |
| Alcohol-related disorders | 0.89 (0.37–2.16) | 1.76 (0.44–7.14) | Not estimated |
| Rheumatoid arthritis | 0.96 (0.36–2.56) | 1.06 (0.15–7.65) | 0.58 (0.08–4.14) |
| Systemic lupus erythematosus | Not estimated | Not estimated | Not estimated |
| Co-medication (within 180 days before T0) | |||
| Systemic corticosteroids | 0.97 (0.77–1.21) | 1.00 (0.62–1.59) | 1.12 (0.80–1.58) |
| NSAIDs | 1.00 (0.88–1.13) | 0.97 (0.74–1.29) | 0.89 (0.72–1.09) |
| Beta-blockers | 1.17 (0.95–1.44) | 0.92 (0.58–1.46) | 1.23 (0.89–1.72) |
| CCBs | 1.00 (0.80–1.25) | 1.11 (0.70–1.77) | 1.49 (1.05–2.13) |
| ACEI | 0.99 (0.74–1.32) | 0.89 (0.48–1.64) | 0.89 (0.55–1.42) |
| ARBs | 1.05 (0.80–1.38) | 0.81 (0.43–1.51) | 1.10 (0.71–1.70) |
| Statin | 0.88 (0.62–1.26) | 0.51 (0.19–1.33) | 0.70 (0.37–1.29) |
| Diuretics | 0.91 (0.47–1.78) | 0.80 (0.19–3.26) | 0.51 (0.13–2.06) |
| Vitamin K antagonists | 0.58 (0.14–2.33) | Not estimated | 1.31 (0.32–5.38) |
| Heparin preparations | 0.85 (0.21–3.47) | Not estimated | 1.86 (0.44–7.79) |